CivicaScript®, LLC, a nonprofit company dedicated to bringing low-cost generic medicines to U.S. patients, today announced the availability of generic dalfampridine extended release tablets. Dalfampridine is a potassium channel blocker indicated to improve walking in certain adult patients with multiple sclerosis (MS). Specific information about the use of dalfampridine can be found here.

CivicaScript will offer dalfampridine 10 mg extended-release tablets for sale to pharmacies for $16 per bottle of 60 tablets – typically a month’s supply. CivicaScript recommends that pharmacies charge patients no more than $37 per bottle (CivicaScript’s maximum retail price, or MaxRPTM).

CivicaScript’s MaxRP policy provides a way for healthcare providers, caregivers, patients and others to compare prices; consumers can confirm they are being charged no more than the MaxRP by scanning the QR code featured on the CivicaScript product label.

CivicaScript’s MaxRP for dalfampridine is about $960 per month less than the average claim cost for prescriptions filled at traditional PBM-affiliated pharmacies¹. It could significantly reduce patients’ out-of-pocket costs during the deductible phase of their health insurance, in which they pay full price for their medicines. Savings also could be substantial for patients with co-insurance, which charges them a percentage of their medicines’ price.

“We’ve brought four new products to market just this year, saving money for patients and payers while transforming the system along the way,” said CivicaScript President Brent J. Eberle. “We’ve shown that when you create transparency and align all stakeholders to prioritize sustainable low costs, everyone benefits.”

A recent report in The New England Journal of Medicine Catalyst showed that CivicaScript’s first product, abiraterone, saved consumers 64% and payers 92% when they switched from other manufacturers.

CivicaScript partners with manufacturers to produce low-cost generic medicines, then works with payers and pharmacies across the country to pass along the cost savings to patients. CivicaScript’s business model focuses on transparency and collaboration throughout the value chain from manufacturing through dispensing — with every stakeholder along the way knowing the price of the medicine and driving savings through to the patient.

Dalfampridine was chosen by CivicaScript members as a priority generic medicine based on its high list price from other manufacturers and significant patient need for the product.

While many generic medicines cost less than brand-name drugs, some high-cost generics are more expensive than they need to be. Numerous studies confirm that medication costs can dictate whether patients ration their prescriptions or even fill them in the first place.^2,3,4

About CivicaScript 
CivicaScript is bringing unprecedented transparency to the drug supply chain to make quality generic medicines affordable and available for everyone. A not-for-profit, limited liability company, CivicaScript is committed to the principles of providing affordable, essential generic medicines to promote the social welfare and health of the community. For more information on the organization and our mission, visit our website. CivicaScript is the Civica, Inc. operating unit for outpatient medications to help drive affordability and price transparency.

About dalfampridine
For full prescribing information and patient information, including warnings and precautions, potential adverse reactions and drug interactions, please refer to the Package Insert, available here. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

MEDIA CONTACT:
Liz Power
liz.power@civicarx.org
+1 860 501 3849